Biotinylation enhances the anticancer effects of 15d‑PGJ2 against breast cancer cells

  • Authors:
    • Christelle Colin
    • Maxime Meyer
    • Claudia Cerella
    • Alexandra Kleinclauss
    • Gérald Monard
    • Michel Boisbrun
    • Marc Diederich
    • Stéphane Flament
    • Isabelle Grillier-Vuissoz
    • Sandra Kuntz
  • View Affiliations

  • Published online on: March 28, 2018     https://doi.org/10.3892/ijo.2018.4338
  • Pages: 1991-2000
Metrics: HTML 0 views | PDF 0 views     Cited By (CrossRef): 0 citations

Abstract

15-Deoxy-∆12,14-prostaglandin J2 (15d‑PGJ2) is a natural agonist of peroxisome proliferator-activated receptor γ (PPARγ) that displays anticancer activity. Various studies have indicated that the effects of 15d‑PGJ2 are due to both PPARγ-dependent and -independent mechanisms. In the present study, we examined the effects of a biotinylated form of 15d‑PGJ2 (b‑15d‑PGJ2) on hormone-dependent MCF‑7 and triple‑negative MDA‑MB‑231 breast cancer cell lines. b‑15d‑PGJ2 inhibited cell proliferation more efficiently than 15d‑PGJ2 or the synthetic PPARγ agonist, efatutazone. b‑15d‑PGJ2 was also more potent than its non-biotinylated counterpart in inducing apoptosis. We then analyzed the mechanisms underlying this improved efficiency. It was found not to be the result of biotin receptor-mediated increased incorporation, since free biotin in the culture medium did not decrease the anti-proliferative activity of b‑15d‑PGJ2 in competition assays. Of note, b‑15d‑PGJ2 displayed an improved PPARγ agonist activity, as measured by transactivation experiments. Molecular docking analyses revealed a similar insertion of b‑15d‑PGJ2 and 15d‑PGJ2 into the ligand binding domain of PPARγ via a covalent bond with Cys285. Finally, PPARγ silencing markedly decreased the cleavage of the apoptotic markers, poly(ADP-ribose) polymerase 1 (PARP‑1) and caspase‑7, that usually occurs following b‑15d‑PGJ2 treatment. Taken together, our data indicate that biotinylation enhances the anti-proliferative and pro-apoptotic activity of 15d‑PGJ2, and that this effect is partly mediated via a PPARγ-dependent pathway. These results may aid in the development of novel therapeutic strategies for breast cancer treatment.

Related Articles

Journal Cover

June 2018
Volume 52 Issue 6

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Colin, C., Meyer, M., Cerella, C., Kleinclauss, A., Monard, G., Boisbrun, M. ... Kuntz, S. (2018). Biotinylation enhances the anticancer effects of 15d‑PGJ2 against breast cancer cells. International Journal of Oncology, 52, 1991-2000. https://doi.org/10.3892/ijo.2018.4338
MLA
Colin, C., Meyer, M., Cerella, C., Kleinclauss, A., Monard, G., Boisbrun, M., Diederich, M., Flament, S., Grillier-Vuissoz, I., Kuntz, S."Biotinylation enhances the anticancer effects of 15d‑PGJ2 against breast cancer cells". International Journal of Oncology 52.6 (2018): 1991-2000.
Chicago
Colin, C., Meyer, M., Cerella, C., Kleinclauss, A., Monard, G., Boisbrun, M., Diederich, M., Flament, S., Grillier-Vuissoz, I., Kuntz, S."Biotinylation enhances the anticancer effects of 15d‑PGJ2 against breast cancer cells". International Journal of Oncology 52, no. 6 (2018): 1991-2000. https://doi.org/10.3892/ijo.2018.4338